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Circulating levels of fibroblast growth factor 23 (FGF23) are
elevated in patients with early chronic kidney disease (CKD)
and are postulated to cause low blood levels of 1,25-
dihydroxyvitamin D, as well as normal phosphate levels. In
order to provide more direct evidence for the
pathophysiological role of FGF23 in the settings of mineral
ion homeostasis typically seen in early CKD, we studied rats
with progressive CKD treated with anti-FGF23 neutralizing
antibody. Without antibody treatment, rats with CKD
exhibited high circulating levels of FGF23 and parathyroid
hormone, low 1,25-dihydroxyvitamin D, and normal serum
phosphate levels, accompanied by increased fractional
excretion of phosphate. Antibody treatment, however,
lessened fractional excretion of phosphate, thus increasing
serum phosphate levels, and normalized serum 1,25-
dihydroxyvitamin D by increased 1a-OHase and decreased
24-OHase expressions in the kidney. These antibody-induced
changes were followed by increased serum calcium levels,
leading to decreased serum parathyroid hormone. Hence,
our study shows that FGF23 normalizes serum phosphate
and decreases 1,25-dihydroxyvitamin D levels in early-stage
CKD, and suggests a pathological sequence of events for the
development of secondary hyperparathyroidism triggered by
increased FGF23, followed by a reduction of 1,25-
dihydroxyvitamin D and calcium levels, thereby increasing
parathyroid hormone secretion.
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Abnormal regulation of mineral ion homeostasis is one of
the major problems in patients with chronic kidney disease
(CKD). A decrease in the number of functional nephrons
has long been thought to lead to impaired urinary phos-
phate excretion and hyperphosphatemia, and to reduced
activity of the renal 25-hydroxyvitamin D-1a-hydroxylase
(1a-OHase) and consequently low 1,25-dihydroxyvitamin D
(1,25(OH)2D) levels. Both changes were thought to result
in hypocalcemia, thereby causing an increase in parathyroid
hormone (PTH) secretion and thus secondary hyperpar-
athyroidism.1,2 This interpretation, however, may need to be
revised to include fibroblast growth factor 23 (FGF23)
actions.
FGF23 is a physiologically important hormone that
decreases serum levels of both phosphate and
1,25(OH)2D.
3,4 Abnormally increased circulating FGF23 are
known to cause hypophosphatemic rickets/osteomalacia
accompanied by inappropriately low levels of circulating
1,25(OH)2D, such as X-linked hypophosphatemia, autosomal
dominant and recessive hypophosphatemia, and tumor-
induced osteomalacia.5–10 Patients with CKD can also present
clear elevations of circulating FGF23 levels, which typically
develop early in the course of CKD.11–13 Circulating FGF23
appears to be intact and biologically active in CKD patients,
even when circulating levels of the immunoreactive FGF23
are dramatically elevated as in patients with end-stage renal
disease.14 It is therefore likely that increased levels of
circulating FGF23 target the remnant nephrons in patients
with early-stage CKD, thereby enhancing fractional excretion
of phosphate (FEPi) and inhibiting the production of
1,25(OH)2D. In fact, frank hyperphosphatemia does not
develop until later stages of CKD when the glomerular
filtration rate drops to o30ml/min.15 In addition, recent
clinical studies have shown that FGF23 independently
correlates with low 1,25(OH)2D and normal phosphate
levels,16,17 suggesting the pathophysiological importance of
increased FGF23.
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The aim of this study is to provide evidence that concludes
a pathophysiological role of FGF23 in the abnormal
regulation of mineral metabolism. To address this, we
developed progressive CKD model rats and analyzed the
effect of anti-FGF23 monoclonal antibodies that block the
activity of endogenous circulating FGF23.18,19
RESULTS
Progressive nephritis was induced in Wistar-Kyoto rats by
singly injecting an anti-glomerular basement membrane
(GBM) antiserum.20 Serum creatinine levels in the rats,
which had received the anti-GBM antiserum (CKD rats),
started to increase from day 10 (10 days after the injection of
the anti-GBM antiserum), followed by progressive changes in
mineral parameters (Figure 1).
CKD rats did not develop significant hyperphosphatemia
until day 30. A major decrease in the circulating levels of
1,25(OH)2D (to 10% of baseline) was observed by day 20.
This model also exhibited mild but statistically significant
hypocalcemia after day 10, which was not progressive and
normalized by days 40–50. The low levels of both 1,25(OH)2D
and calcium presumably caused increased circulating PTH
levels starting on day 20. Serum FGF23 levels showed a
moderate but significant increase by day 10 and rapidly
increased thereafter. Thus, before day 30, the rats with anti-
GBM nephritis mimicked, with the exception of low blood
calcium levels, most of the abnormalities in mineral ion
homeostasis typically seen in patients with early-stage CKD.
Therefore, we focused on this time period in analyzing the
actions of FGF23.
Additional CKD rats were developed, and blood and urine
analyses on day 28 showed similar laboratory data in mineral
metabolism as observed in Figure 1 (Table 1). Of note, CKD
rats again did not develop significant hyperphosphatemia,
but we found a 65% increase in FEPi (Table 1). These CKD
animals were divided into three groups and were then treated
with either vehicle (phosphate-buffered saline) or two
different doses of anti-FGF23 antibodies (0.1 or 1mg/kg) as
an intravenous single injection on day 32. Subsequently,
changes in serum levels of phosphate, calcium, PTH, and
1,25(OH)2D, as well as FEPi, were monitored for up to 72 h
after the antibody injection.
Treatment with anti-FGF23 antibodies resulted in marked
elevations in serum phosphate levels that were dependent on
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Figure 1 |Time course of changes in serum parameters of rats with anti-GBM nephritis. On day 0, WKY rats were injected with a rabbit
anti-rat GBM serum (CKD, N¼ 8) or an equivalent volume of normal rabbit serum (Normal, N¼ 8). On days 0, 10, 20, 30, 40, and 50, blood
samples were sequentially collected from tail artery and sera were prepared. Results represent mean±s.e.m. ***Po0.001, **Po0.01,
*Po0.05; normal vs CKD group on each day. 1,25(OH)2D, 1,25-dihydroxyvitamin D; Ca, calcium; CKD, chronic kidney disease; FGF23, fibroblast
growth factor 23; GBM, glomerular basement membrane; Pi, phosphate; PTH, parathyroid hormone; WKY, Wistar-Kyoto.
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the dose of antibody and lasted, in rats given the higher dose,
for 448 h (Figure 2a). In association with the increased
serum Pi levels, FEPi decreased within 24 h after the treatment
with anti-FGF23 antibodies (Figure 2b).
The injection of anti-FGF23 antibodies also induced a
dramatic increase in serum 1,25(OH)2D levels, such that they
reached normal levels, which lasted for at least 72 h in the
group that had received the higher dose of the antibodies
(Figure 3a). These increases in the biologically active form of
vitamin D were accompanied in kidney by equivalent changes
in the levels of the mRNAs encoding vitamin D-metabolizing
enzymes (Figure 3b). In comparison to vehicle-injected
normal animals, CKD rats showed about 50% reduction in
the renal expression of the 1a-OHase, whereas the expression
of 25-hydroxyvitamin D-24-hydroxylase (24-OHase) in-
creased by approximately fivefold. The antibody treatment
dramatically increased the expression of the 1a-OHase,
whereas decreasing that of the 24-OHase within 8 h.
The recovery in serum 1,25(OH)2D levels was followed by
increased serum calcium levels after 48 h in the antibody-
treated CKD rats (Figure 4). In addition, blocking FGF23
action in CKD rats resulted in moderate suppression of
circulating levels of PTH (Figure 4). Because this change
occurred after the recovery of both serum 1,25(OH)2D and
calcium, the suppression of PTH is likely because of the effect
of the elevations of 1,25(OH)2D and calcium.
DISCUSSION
We demonstrated that the inhibition of FGF23 activity in rats
with mild CKD resulted in high serum phosphate and
normal 1,25(OH)2D levels. These findings indicate that
normal phosphate and low 1,25(OH)2D in these rats are
FGF23-dependent changes, and are compatible with the
clinical observations that circulating levels of FGF23
correlated well with FEPi or lowered 1,25(OH)2D levels in
patients with early-stage CKD.16,17
FEPi was high in rats with mild CKD and decreased after
the treatment with anti-FGF23 antibodies. This indicates that
FGF23 inhibits renal phosphate reabsorption in mild CKD,
thereby maintaining serum phosphate levels within the
reference range. In other words, phosphate retention
appeared to be mitigated by compensatory FGF23 actions,
although glomerular filtration rate was already significantly
reduced. This is compatible with the clinical observations
that circulating levels of FGF23 tended to show a better
correlation with FEPi than serum phosphate levels in patients
with mild CKD.16,17
Table 1 | Blood and urinary parameters in anti-GBM nephritis
on day 28
Normal (N=8) CKD (N=30) P-values
Creatinine (mg/dl) 0.67±0.03 1.22±0.05 o0.001
Pi (mg/dl) 7.2±0.2 7.2±0.1 0.813
1,25(OH)2D (pg/ml) 179.2±23.1 24.9±2.9 o0.001
Ca (mg/dl) 10.0±0.1 9.5±0.1 o0.005
PTH (pg/ml) 37.4±3.1 181.1±16.7 o0.001
FGF23 (pg/ml) 227.2±7.7 640.1±41.3 o0.001
FEPi (%) 16.6±1.4 27.5±1.3 o0.001
Abbreviations: Ca, calcium; CKD, chronic kidney disease; FEPi, fractional excretion of
phosphate; FGF23, fibroblast growth factor 23; PTH, parathyroid hormone; GBM,
glomerular basement membrane; Pi, phosphate.
WKY rats were injected with a rabbit anti-rat GBM serum (CKD, N=30) or
an equivalent volume of normal rabbit serum (Normal, N=8). On day 28, blood
samples were collected from tail artery and sera were prepared. Urine samples were
collected in metabolic cages for 24 h and FEPi was determined. Results represent
mean±s.e.m. and statistical significance was evaluated using Student’s t-test.
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Figure 2 | Effects of anti-FGF23 antibodies on phosphate
metabolism in rats with anti-GBM nephritis. On day 32, CKD
rats were injected with PBS (CKDþ vehicle, N¼ 10) or anti-FGF23
neutralizing antibodies at 0.1mg/kg (CKDþAb (0.1), N¼ 10) or
1.0mg/kg (CKDþAb (1), N¼ 10). As a reference, normal WKY rats
at the same age were treated with an equivalent volume of PBS
(Normal, N¼ 8). (a) Time course of changes in serum phosphate
levels. Blood samples were collected from tail artery at 0
(before the injection), 24, 48, and 72 h after the injection.
Results represent mean±s.e.m. ***Po0.001, *Po0.05;
CKD-vehicle group vs CKD-Ab groups. (b) FEPi after treatment
with antibodies. Rats in reference group (Normal, N¼ 8), CKD
groups treated with vehicle (CKDþ vehicle, N¼ 8) or anti-FGF23
antibodies at 1mg/kg (CKDþAb, N¼ 10) were reared individually
in a metabolic cage after the injection and 24-h urine samples
were collected for 2 days. FEPi was calculated using the formula
(phosphate clearance)/(creatinine clearance). ***Po0.001.
CKD, chronic kidney disease; FEPi, fractional excretion of phosphate;
FGF23, fibroblast growth factor 23; GBM, glomerular basement
membrane; PBS, phosphate-buffered saline; Pi, phosphate;
WKY, Wistar-Kyoto.
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Because hyperphosphatemia is known to be one of the risk
factors for vascular calcification, and the severe vascular
calcification seen in Fgf23 knockout mice has been shown to
be caused by hyperphosphatemia,21 maintaining serum
phosphate levels by FGF23 may in part contribute to prevent
the development of vascular calcifications in early CKD.
It is of interest that the injection of antibodies increased
serum phosphate levels despite continuously high circulating
levels of PTH. Although a mild decrease in PTH levels was
observed after 48 h, changes in both serum and urinary
phosphate occurred before this reduction of PTH. Therefore,
the observed hyperphosphatemia resulted from the inhibition
of FGF23 action, independently of PTH, suggesting that
although further experiments are required, FGF23 has, at
least in the early stages of CKD, a more important role in
renal phosphate handling than PTH. This is consistent with
previous observations in humans showing that the circulating
levels of FGF23 but not PTH are correlated with serum
phosphate levels.17
Our study also provides evidence that increased FGF23
action, in addition to a loss of healthy nephrons, is another
driving force by which serum levels of 1,25(OH)2D
significantly decrease in early-stage CKD. Given that the
administration of a phosphate binder reduced circulating
levels of FGF23 in CKD rats,22 the previous observation that
dietary phosphate restriction reversed the low 1,25(OH)2D
levels in patients with moderate CKD23 can be interpreted as
a result of a decrease in circulating levels of FGF23. Another
important point illuminated by our study is that the
continuously high circulating level of PTH in early CKD,
which should increase renal expression of 1a-OHase, cannot
maintain normal circulating 1,25(OH)2D levels. This implies
that in early CKD, FGF23 action on the regulation of
1,25(OH)2D is more dominant than that of PTH.
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Figure 3 | Effects of anti-FGF23 antibodies on vitamin D
metabolism in rats with anti-GBM nephritis. (a) Time course
of changes in serum 1,25(OH)2D levels. Blood samples were
collected from tail artery at 0 (before the injection), 24, 48,
and 72 h after the injection. Results represent mean±s.e.m.
***Po0.001, **Po0.01, *Po0.05; CKD-vehicle group vs CKD-Ab
groups. $$$Po0.001; normal group vs CKD-vehicle group.
(b) Quantitative PCR analyses for mRNA levels of renal 1a-OHase
and 24-OHase. Anti-FGF23 antibodies (1mg/kg) or vehicle
was injected and kidney samples (Normal, N¼ 3; CKDþ vehicle,
N¼ 5; CKDþAb, N¼ 5, respectively) were collected at 8 h
after the injection. Results represent mean±s.e.m. *Po0.05.
1,25(OH)2D, 1,25-dihydroxyvitamin D; CKD, chronic kidney
disease; FGF23, fibroblast growth factor 23; GBM, glomerular
basement membrane.
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Figure 4 | Effects of anti-FGF23 antibodies on calcium and PTH
levels in rats with anti-GBM nephritis. Blood samples were
collected from tail artery at 0 (before the injection), 24, 48, and
72 h after the injection. Results represent mean±s.e.m.
***Po0.001, **Po0.01, *Po0.05; CKD-vehicle group vs CKD-Ab
groups. $$$Po0.001, $$Po0.01; normal group vs CKD-vehicle
group. Ca, calcium; CKD, chronic kidney disease; FGF23, fibroblast
growth factor 23; GBM, glomerular basement membrane;
PTH, parathyroid hormone.
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Treatment with antibodies resulted in the mild decrease in
serum PTH level, which was probably caused by elevations of
both serum calcium and 1,25(OH)2D levels. In this regard,
our finding suggests the sequence of events in the pathogen-
esis of secondary hyperparathyroidism in early-stage CKD.
Presumably, the elevation of PTH per se was necessary to
prevent an even more severe hypocalcemia that could be caused
by the significantly low serum 1,25(OH)2D induced by FGF23.
This condition may be consistent with the settings in mice
carrying the cells overexpressing recombinant FGF23, where
the continuous action of FGF23 caused low serum levels of
1,25(OH)2D and calcium, thereby developing secondary hyper-
parathyroidism.24 Thus, although the first trigger by which
FGF23 increases remains unclear, our finding suggests that
the same sequence underlies the enhanced PTH secretion in
early CKD, leading to secondary hyperparathyroidism.
Our study raised a question on the impact of direct action
of FGF23 on the parathyroid gland. FGF23 has been shown to
directly suppress PTH expression/secretion through an
essential co-receptor for FGF23 signaling, Klotho.25,26 How-
ever, it is known that circulating levels of FGF23 are positively
associated with those of PTH even in mild CKD,16 which was
reproduced in our CKD rats as well. Furthermore, treatment
with FGF23 antibodies did not increase circulating PTH, but
rather reduced serum PTH levels, probably because of the
normalized 1,25(OH)2D and increased calcium levels. These
suggest that there is a resistance or insensitivity to FGF23 in
the parathyroid gland, which may be, in part, explained by
the recent finding that Klotho and FGF receptor expressions
in this organ were reduced in patients with end-stage renal
disease.27 Even if FGF23 could target the parathyroid gland
and regulate PTH secretion in early CKD, our finding
suggests that the action of calcium or 1,25(OH)2D is more
potent than that of FGF23 on PTH secretion. Thus, the
FGF23-dependent regulation of PTH is unlikely to have a
dominant role at least in early CKD.
In summary, our study provides direct evidence for the
conclusion that high levels of circulating FGF23 in early-stage
CKD mitigate phosphate retention and cause low levels of
circulating 1,25(OH)2D, confirming recent clinical observa-
tions. Based on these findings, it may be necessary to revise
current hypotheses regarding the mechanisms that result in
the development of abnormal mineral ion homeostasis in
CKD, and to develop strategies to prevent the development of
secondary hyperparathyroidism.
MATERIALS AND METHODS
Experimental anti-GBM nephritis
The experimental protocol was approved by the experimental
animal ethical committee of Kirin Pharma. Rabbit anti-rat GBM
serum was prepared in our laboratory according to the previ-
ously published method.20 Anti-GBM nephritis was established by
singly injecting 9-week-old male Wistar-Kyoto rats (Charles River,
Tokyo, Japan) with rabbit anti-rat GBM serum via tail vein. Normal
rats were injected with an equivalent volume of normal rabbit
serum (Funakoshi, Tokyo, Japan). Blood samples were sequentially
collected from the tail artery on the indicated days. All rats were fed
a standard rodent chow CE-2 (Crea, Japan) containing 1% calcium
and 1% phosphate and tap water ad libitum.
Serum and urine chemistries
Serum and urine levels of phosphate and calcium were measured by
test Wako kits (Wako Pure Chemical Industries, Osaka, Japan). Serum
and urine creatinine levels were measured by CRE-EN kit (Kainos,
Tokyo, Japan). Serum PTH and 1,25(OH)2D levels were measured
using rat PTH-(1–34) immunoradiometric assay (Immutopics, San
Clemente, CA, USA) and 1,25(OH)2D radioimmunoassay (TFB,
Immunodiagnostic System, Tyne and Wear, UK), respectively. Serum
FGF23 levels were determined with intact FGF23 assay kit (Kainos).
Anti-FGF23 antibody
Anti-FGF23 neutralizing antibodies used in this study were 1:1
mixtures of mouse monoclonal antibodies that recognize either the
N-terminal receptor-binding domain or the C-terminal Klotho-binding
region and have synergistic effects in vivo.18 Antibodies were affinity-
purified by protein G sepharose 4FF (GE Healthcare, Buckinghamshire,
UK) and stored in phosphate-buffered saline without any other
supplements.
Real-time quantitative PCR analysis
Total RNAs were extracted from kidneys using RNeasy Mini Kit
(Qiagen, Valencia, CA, USA), and were used to prepare comple-
mentary DNA by reverse transcription using SuperScript III First
Strand Synthesis System RT kit (Life Technologies, Carlsbad, CA, USA).
Real-time quantitative PCR was performed using the ABI7900HT
system and the following TaqMan Expression Assay Primers (Life
Technologies): Cyp27b1:Rn00587137, Cyp24:Rn01423141, and b-actin:
Rn00667869.
Statistics
All data were analyzed using SAS analytics software (SAS Institute,
Tokyo, Japan). All values represent means±s.e.m. Statistical significance
between CKD and normal groups was analyzed using nested analysis of
variance, followed by Student’s t-test at each time point. Pharmacolo-
gical effects of anti-FGF23 neutralizing antibodies at each time point
were evaluated using parametric Dunnett’s test after a nested analysis of
variance. The P-value of o0.05 was considered statistically significant.
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